SCHEMBL4469287

SCHEMBL4469287

COC(=O)CNC(=O)c1ccc(C(=O)N(N)c2ccccc2)nc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 3/20 0.43
STAMBP O95630 1/20 0.43
P4HTM Q9NXG6 4/20 0.41
KDM4E B2RXH2 4/20 0.41
ALDH1A1 P00352 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
AHR P35869 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TSHR P16473 1/20 0.41
HSD17B10 Q99714 1/20 0.41
VEGFA P15692 2/20 0.41
FLT1 P17948 2/20 0.41
XDH P47989 2/20 0.41
EGLN3 Q9H6Z9 1/20 0.40
MAPK1 P28482 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4486555 0.91 EGLN1 (0.43) EGLN1STAMBPP4HTMKDM4EALDH1A1
SCHEMBL4478208 0.83 GABRA5 (0.40) P4HTMKDM4EALDH1A1NPC1RAB9A
SCHEMBL4481743 0.77 TAS1R3 (0.46) P4HTMKDM4EALDH1A1NPC1RAB9A
SCHEMBL4469281 0.76 MEN1 (0.56) P4HTMMEN1KMT2AAHR
SCHEMBL4496850 0.75 DGAT2 (0.38) P4HTMKDM4EALDH1A1NPC1RAB9A
SCHEMBL4490213 0.74 L3MBTL1 (0.52) ALDH1A1MEN1KMT2AL3MBTL1GAA
SCHEMBL4486547 0.73 MEN1 (0.58) P4HTMMEN1KMT2AAHR
SCHEMBL8869868 0.73 P4HTM (0.66) P4HTMKDM4EALDH1A1NPC1RAB9A
SCHEMBL3961994 0.71 GAA (0.59) KDM4EALDH1A1NPC1RAB9AMEN1
SCHEMBL8870393 0.70 P4HTM (0.49) EGLN1P4HTMVEGFAFLT1EGLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071219-B2 Mono-acylated o-phenylendiamines derivatives HOFFMANN-LA ROCHE INC. (US) 2006-07-04 US claimed
EP-1592667-A2 NEW MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-11-09 EP claimed
WO-2004069803-A2 MONO-ACYLATED O-PHENYLENDIAMINES DERIVATIVES AND THEIR USE AGAINST CANCER F. HOFFMANN-LA ROCHE AG (CH) 2004-08-19 WO claimed
US-20040162317-A1 Mono-acylated o-phenylendiamines derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2004-08-19 US claimed
US-7501451-B2 Mono-acylated o-phenylendiamines derivatives HOFFMANN-LA ROCHE INC. (US) 2009-03-10 US disclosed
US-7071219-B2 Mono-acylated o-phenylendiamines derivatives HOFFMANN-LA ROCHE INC. (US) 2006-07-04 US disclosed
US-20060089403-A1 Mono-acylated o-phenylendiamines derivatives FERTIG GEORG 2006-04-27 US disclosed
US-20040162317-A1 Mono-acylated o-phenylendiamines derivatives F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2004-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060089403-A1 Mono-acylated o-phenylendiamines derivatives HDAC1, HDAC10, HDAC11 EGLN1 409/4885STAMBP 4653/4885P4HTM 692/4885
US-20040162317-A1 Mono-acylated o-phenylendiamines derivatives HDAC1, HDAC11, HDAC10 EGLN1 609/4885STAMBP 4794/4885P4HTM 1825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.